Ng Cecilia H M, Michelmore Andrew G, Mishra Gita D, Montgomery Grant W, Rogers Peter, Abbott Jason
C Ng, School of Clinical Medicine, Medicine and Health, Division of Obstetrics and Gynaecology, University of New South Wales, Randwick, Australia.
A Michelmore, Research Partnerships, Jean Hailes for Women's Health, East Melbourne, Australia.
Reprod Fertil. 2023 May 1;4(2). doi: 10.1530/RAF-23-0014.
Endometriosis is a common yet under-recognised chronic inflammatory disease, affecting 176 million women, trans and gender diverse people globally. The National Endometriosis Clinical and Scientific Trials (NECST) Registry is a new clinical registry, collecting and tracking diagnostic and treatment data, and patient-reported outcomes on people with endometriosis. The registry is a research priority action item from the 2018 National Action Plan for Endometriosis and aims to provide, large-scale, national and longitudinal population-based data on endometriosis. Working groups (consisting of patients with endometriosis, clinicians and researchers) developing the NECST Registry data dictionary and data collection platform started in 2019. Our data dictionary was developed based on existing and validated questionnaires, tools, meta-data and data cubes - World Endometriosis Research Foundation (WERF) Endometriosis Phenome and Biobanking Harmonisation Project (EPHect), endometriosis CORE outcomes set, patient-reported outcome measures, the International Statistical Classification of Diseases-10th Revision Australian Modification diagnosis codes, and Australian Government datasets: Australian Institute for Health and Welfare (for sociodemographic data), Medicare Benefits Schedule (MBS; for medical procedures) and the Pharmaceutical Benefits Scheme (PBS; for medical therapies). The resulting NECST Registry is an online, secure cloud-based database; prospectively collecting minimum core clinical and health data across eight patient and clinician modules and longitudinal data tracking disease life course. The NECST Registry has ethics approval (HREC/62508/MonH-2020) and is registered on the Australian New Zealand Clinical Trials Registry (ACTRN12622000987763).
子宫内膜异位症是一种常见但未得到充分认识的慢性炎症性疾病,全球有1.76亿女性、跨性别者及性别多样化人群受其影响。国家子宫内膜异位症临床与科学试验(NECST)登记处是一个新的临床登记处,收集和跟踪诊断及治疗数据,以及子宫内膜异位症患者报告的结局。该登记处是2018年国家子宫内膜异位症行动计划中的一项研究优先行动项目,旨在提供关于子宫内膜异位症的大规模、基于全国人口的纵向数据。制定NECST登记处数据字典和数据收集平台的工作组(由子宫内膜异位症患者、临床医生和研究人员组成)于2019年启动。我们的数据字典是基于现有的经过验证的问卷、工具、元数据和数据立方体开发的——世界子宫内膜异位症研究基金会(WERF)子宫内膜异位症表型与生物样本库协调项目(EPHect)、子宫内膜异位症核心结局集、患者报告结局测量、国际疾病分类第10次修订本澳大利亚修订版诊断代码,以及澳大利亚政府数据集:澳大利亚卫生与福利研究所(用于社会人口数据)、医疗保险福利计划(MBS;用于医疗程序)和药品福利计划(PBS;用于药物治疗)。由此产生的NECST登记处是一个在线的、基于安全云的数据库;前瞻性地收集八个患者和临床医生模块中的最低核心临床和健康数据,以及跟踪疾病病程的纵向数据。NECST登记处已获得伦理批准(HREC/62508/MonH - 2020),并已在澳大利亚新西兰临床试验登记处注册(ACTRN12622000987763)。